Aldeyra Therapeutics announced on Tuesday that its President and Chief Executive Officer, Dr. Todd C. Brady, will participate in the 2026 Jefferies Global Healthcare Conference and engage in a fireside chat.

According to the company's announcement, the conversation between Dr. Brady and Jefferies Biotechnology Equity Research Vice President Amin Makarem is scheduled for Thursday, June 4, at 8:45 a.m. Eastern Time in New York. Interested investors can view a live webcast via the investor relations section of Aldeyra's corporate website. A replay will be archived on the site for 90 days following the conference.

Aldeyra Therapeutics Inc (NASDAQ: ALDX)

Aldeyra Therapeutics is a biotechnology company focused on discovering and developing innovative therapies to treat immune-mediated diseases. The company's technology approach emphasizes developing drugs that modulate protein systems, rather than directly inhibiting or activating a single protein target, with the goal of simultaneously optimizing multiple pathways while minimizing toxicity.

The company's product pipeline includes RASP modulators ADX-248 and ADX-246, along with related molecules, for the potential treatment of systemic and retinal immune-mediated diseases. Its late-stage development candidates include reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel intravitreal methotrexate formulation for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

The Jefferies Global Healthcare Conference is a major industry investor event, bringing together public and private companies from the global biotechnology, pharmaceutical, and healthcare sectors. The conference provides investors with an opportunity to learn about Aldeyra's latest business developments and pipeline strategy.